Acelyrin raises $250m through Series B round
Acelyrin has raised $250m through the series B financing round to license and acquire other programmes with focus on immunology. The funding round was led by Matrix Capital
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation by the European regulatory authorities for Novo Nordisk’s anti-obesity medication Wegovy.